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Summary A detailed study was performed in 14 patients with epithelial ovarian tumours using the satellite
probes 33.15, 228S and 216S to investigate the nature of somatic changes and frequency with which clonal
changes could be demonstrated during metastasis and progression. Somatic changes were evident in approx-
imately 70% of ovarian tumours, the most common being a deletion or reduction in intensity of a band
suggesting loss of heterozygosity. Additional changes that were observed included increased intensification of
single bands and the appearance of novel DNA fragments. Somatic alterations were seen following digestion
of DNA with methylation resistant restriction endonucleases indicating that methylation differences alone
could not account for all of the somatic changes. Using DNA fingerprint analyis ovarian tumours were shown
to be heterogeneous with different DNA patterns observed in different sites in five of eight patients. Generally,
within an individual patient the primary and metastases appeared to share a DNA fingerprint pattern with
minor variations occurring in different sites suggesting that different populations have derived from a common
stem line. This study clearly demonstrates that DNA fingerprint analysis is a sensitive method to detect
somatic changes in tumour DNA and for investigating the development of clonal heterogeneity in ovarian
tumours.
Ovarian cancer is a major cause of female cancer deaths yet
relatively little is known of the genetic events associated with
the development or subsequent metastasis and progression of
epithelial ovarian tumours. Complex karyotypic changes
have been observed, and although certain non-random
abnormalities have been reported (Wake et al., 1980; Whang-
Peng et al., 1984) in particular involving 6q - and 14q +,
these have not been confirmed in subsequent studies and no
unique or consistent chromosomal abnormality has been
identified. Cytogenetic analysis has revealed a high incidence
of structural as well as numerical changes that are reflected in
alterations in tumour cellular DNA content (Jakobsen et al.,
1983), which in turn has been shown to reflect the biological
behaviour of ovarian tumours (Friedlander et al., 1984,
1988). Diploid ovarian tumours tend to be more indolent
than aneuploid tumours, and are associated with a more
favourable prognosis, but the reasons for this variability in
biological behaviour are not understood (Friedlander et al.,
1984). Detailed studies into oncogene activation and
deregulation in ovarian cancer have largely been unrewarding
and although amplification or increased expression of several
oncogenes, in particular C-Ki-ras, has been reported, the
incidence is low and significance probably secondary (Boltz
et al., 1989; Van't Veer et al., 1988). Gene loss has recently
been implicated in the development and progression of a
wide range of human tumours, including the common solid
tumours such as breast, lung and colon cancer (Ponder, 1988;
Hansen & Cavanee, 1988). Restriction fragment length
polymorphism (RFLP) analysis using single copy gene probes
can detect allelic loss at a variety of chromosomal loci, but
this approach has not been successful in demonstrating
chromosomal loss in ovarian cancer. RFLPs represent single
markers in search of a disease locus and therefore a wide
panel of polymorphic probes representing different loci may
be necessary to detect chromosomal loss. An alternative ap-
proach to screen for genomic rearrangements and chromo-
somal loss in tumours, however, is now possible using DNA
fingerprint analysis. The DNA fingerprint technique is based
on the existence of multiple hypervariable tandem repetitive
sequences (or minisatellites) that are dispersed throughout
the genome and are highly polymorphic due to allelic varia-
tion in repeat copy number (Jeffreys et al., 1985). DNA
fingerprints demonstrate both somatic and germ line stability
and being completely individual specific makes them partic-
ularly useful in criminal identification and parenthood dis-
putes. Minisatellite probes consisting of the core sequence
repeated in the tandem recognise sequences present on the
majority of human chromosomes rather than on a single
chromosome and provide a set of genetic markers which are
also of value in detecting somatic changes in tumour DNA
(Thein et al., 1987; Fey et al., 1988). We report the results of
a detailed study using both minisatellite and satellite III
DNA probes to investigate the nature of somatic changes
and the frequency with which clonal changes occur during
metastasis and progression of human epithelial ovarian
tumours.
Satellite III DNA is a class of repetitive DNA which
contains a complex 'macrosatellite' polymorphism that has
received little attention despite its ability to produce DNA
fingerprints of exceptional complexity. The family of
sequences classified as satellite III like are characterised by
the presence of a tandem pentameric repeat sequence
TTCCA. The Taq 1/satellite III polymorphism is carried by
approximately one-third of the chromosomal complement
and probably caused by point mutational events (Fowler et
al., 1988).
Materials and methods
Tumour and corresponding non-neoplastic tissue were
obtained from fourteen patients with epithelial ovarian
tumours at the time of the initial staging laparotomy. A
summary of the clinicopathological features of the tumours is
outlined in Table I. Multiple tumour sites were biopsied
where possible and samples snap frozen in liquid nitrogen.
Formalin fixed, paraffin-embedded sections adjacent to the
sample site were prepared and stained with haematoxylin and
eosin for histopathological assessment. Particular care was
taken to reduce 'contamination' of tumour specimens by
surrounding normal tissue as mixing experiments indicated
that at least 40% of the cells used to isolate DNA had to be
tumour cells in order to detect tumour related changes and to
obtain optimum results (data not shown).
DNA was extracted from tumour, non-neoplastic tissue
samples and peripheral blood leucocytes using methods that
have been previously described (Razin & Riggs, 1980; Suther-
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Table I Clinicopathological characteristics
FIGO Histological Histological
Patient stage subtype grade Prior therapy
BE 3 S 3 -
TA 3 S 3 -
GR 3 S 2 -
GA 3 S 3 -
SC 3 S 3 -
DO I S 3 chlorambucil
SM 3 S 3 -
CH 3 S 2 radiotherapy
NO 3 S 3 -
AM 1 E 3 -
WO 3 S 2 -
HY 2 S 3 -
MI 3 E 3 -
HA 1 F - -
S, serous; E, endometrioid; F, benign fibroma.
land et al., 1986). Equivalent amounts of constitutional and
tumour DNA (8-10pg) from each patient were digested
under conditions recommended by the manufacturer (Boeh-
ringer Mannheim, NSW 2113, Australia) with the appropri-
ate DNA restriction endonuclease; Taq I (for use with satel-
lite III probe 228S), Hinf I, Alu I or Hae III (for 33.15) and
Pst I (for 216S). After complete digestion the DNA was
electrophoresed on a 20 cm long 1% agarose gel and run for
30 hours until all fragments less than 1.5 kb had run off the
gel. The DNA was transferred onto Gene Screen Plus
(Biotechnology Systems, Boston, MA, USA) nylon mem-
branes and baked for 2 hours at 80C.
DNA probes
The probes used included a minisatellite probe 33.15 (Jeffreys
et al., 1985), and satellite III or macrosatellite probes 228S
and 216S (Fowler et al., 1988) which were generously pro-
vided by the respective investigators, cloned in ml3 lac
phage. Single stranded phage was radiolabelled with 32P
dCTP via primer extension to high specific activity ranging
from 107 to 109 c.p.m. fig-.
The labelled probes were hybridised with the nylon filters
in 4 x SSPP, 0.5% instant skimmed milk powder ('blotto')
and 1% SDS at 65°C overnight. The filters were washed in
four successive washes of 2 x SSC, 0.1% SDS for 15 minutes
at 37°C; 0.5 x SSC, 0.1% SDS + 150tl' Proteinase K
(20 mg ml-') for 60 minutes at 37°C; 0.1 x SSC, 0.1% SDS
for 30 minutes at 37°C; 0.1 x SSC, 1% SDS for 30 minutes
at 55°C. Filters were exposed to Kodak X-ray film overnight
without intensifying screens.
Results
Multiple tumour samples and corresponding constitutional
DNA from 14 patients with ovarian tumours were analysed
using the mini and macrosatellite probes 33.15 and 228S
respectively. Complex banding patterns were obtained and up
to 42 resolvable hypervariable fragments ranging from 23 to
2 kb in size could be detected using either probe. The DNA
'fingerprint' obtained for each patient was discriminating and
individual specific. The detailed results and comparison of
the banding patterns observed in tumour DNA and corre-
sponding constitutional DNA are summarised in Table II.
Differences between tumours and corresponding constitu-
tional DNA that were observed included: (a) a deletion or
decrease in relative intensity of a band, (b) the appearance of
novel fragments, and (c) amplification or a significant in-
crease in relative intensity of a band. Somatic changes could
be demonstrated in most tumours and a difference in the
banding pattern in tumour DNA was evident in 10 of the 14
patients. The most common variation was a deletion or shift
in the relative intensity of a band/s and this was apparent in
nine of the 14 cases. A relative increase in band intensity or
Table II DNA fingerprint analysis of ovarian tumours
Change in tumour DNA fingerprint
Taq I Hinf I Alu I Hae III
228 S 33.15 33.15 33.15
DNA source N D R A N D R A N D R A NDR A
BE
R. Ovary 0 1 0 0
L. Ovary 0 1 0 0
Rectum 3 1 3 7 2 2
Rectum 0 1 0 0
Met. 0 2 1 0
TA*
R. Ovary 1 2 1
L. Ovary 1 2 1
Omentum 1 2 1
Met. 1 2 1
Colon 1 2 1
GR
R. Ovary 0 0 2 2 1
L. Ovary 1 0 1 1
GA
Ovary 1 1 2
Met. 1 1 3
SC
Ovary 1 1 0
DO*
Ovary 2 2 1 1
Met. 2 2 1 1
SM
Ovary 3 1 2 1
CH
Omentum 1 2 0
NO
R. Ovary 2 2 1 2 1 1
L. Ovary 2 2 2 1
Omentum 2 2 2 2
Met. 2 2 2 1
AM
R. Ovary I
Uterus 2
Only those tumours whose DNA fingerprints differed from
constitutional DNA are shown above. An additional four ovarian
tumours studied had a DNA fingerprint pattern that was indis-
tinguishable from constitutional DNA. Constitutional DNA was
represented by DNA from peripheral blood leucocytes or in some
cases adjacent normal tissue. These were all considered to have the
normal pattern and are not shown in the table. The numbers
represent the number of changes in tumour DNA fingerprint. Met.
indicates metastatic site that was biopsied, in most cases being a
peritoneal deposit. *The tumours where DNA fingerprint was
identical in primary and metastases. N, normal pattern; D, deletion
or reduction in intensity of a band; R, new band; A, amplification or
increased intensity of a band.
amplification was demonstrated in tumours from six patients
while novel fragments were detected in five ovarian car-
cinomas. The DNA fingerprint pattern depended on the
satellite probe as well as the restriction enzyme used to digest
the DNA. Results using 228S/Taq 1 and 33.15/Hinf 1 were
often quite different (see Table II), but were complementary
and additional information was obtained using both probes.
However, all tumours which were probed with 228S/Taq 1
and shown not to differ from corresponding constitutional
DNA were also normal using 33.15/Hinf 1.
Tumours and constitutional DNA were digested with
Alu 1 and/or Hae III and probed with 33.15 to determine
whether the apparent somatic changes were due to specific
DNA methylation which could affect Hinf 1 cleavage sites.
With one exception, changes in the tumour DNA fingerprints
were observed in all tumours that had somatic alterations
demonstrated with 33.15/Hinf 1. However, in four of the
cases at least some of the alterations in relative band inten-
sity that were observed with 33.15/Hinf 1 appeared to beSATELLITE PROBES IN OVARIAN CANCER 25
related to DNA methylation changes. For example, in
patient BE there was an apparent reduction in intensity in a
3.8 kb band in all tumour sites, an additional reduction in
intensity of a 5.5 kb band in a peritoneal metastasis and the
appearance of three new bands in a rectal metastasis when
DNA was digested Hinf 1 and probed with 33.15 (Table II,
Figure la). The DNA pattern obtained following digestion
with Alu 1 showed no evidence of deletion of any bands
apart from reduction in intensity of a 6 kb band in the
peritoneal metastasis, but confirmed the presence of multiple
new bands in the rectal metastasis (Figure lb).
The Hae III digest demonstrated the presence of two new
bands and reduction in intensity of two bands in the rectal
metastasis, but no changes were evident in the other sites.
The stability of the somatic changes in multiple tumour
sites could be investigated in seven informative patients in
whom the tumour DNA differed from constitutional DNA
and where more than one metastatic site was sampled in
addition to the primary. In five such cases (BE, GR, GA,
NO, AM) there was evidence of variability in the DNA
fingerprint pattern in different tumour sites within the same
patient, while in two patients (TA, DO) all the tumour sites
sampled shared somatic alterations in common with the
primary site (Table II). Generally the differences observed
were with alterations evident in only one or two bands in one
or more metastatic sites. However, a particular striking
example of tumour heterogeneity was observed in patient BE
in whom multiple new bands were observed in a solitary
rectal metastasis and deletion of a band in a peritoneal
metastasis (Figure la and b). The histological sections in this
case were carefully reviewed and despite the differences at the
genomic level in different metastatic sites the tumour biopsies
all appeared to be histological identical.
Tumours and constitutional DNA from all patients were
digested with Pst 1 and probed with 216S, a satellite III
DNA probe which gives an invariate banding pattern, in
order to determine whether common non-random deletions
could be detected (Figure 2). However, providing that diges-
tion was complete there appeared to be no differences
observed in the majority of tumours and an identical banding
pattern was obtained in all cases apart from two tumours
with an apparent reduction in intensity of a single common
band.
Discussion
DNA fingerprint analysis is a new and potentially useful
technique to analyse the somatic changes that occur in
tumours and to characterise genetic alterations during
tumour progression. A variety of abnormalities may result in
the alteration of the DNA fingerprint in tumours and these
include unequal chromatid exchange, non-disjunction, aber-
rant mitotic recombination, interstitial deletion and gene
amplification. The technique appears to be sensitive in detect-
ing chromosomal aberrations and it is noteworthy that loss
of fragments in a DNA fingerprint has been shown to occur
when partial deletion of a chromosome is evident on
karyotypic analysis (de Jong et al., 1988). The DNA finger-
prints obtained using the minisatellite probe 33.15 are
derived from approximately 30 loci scattered throughout the
genome (Jeffreys et al., 1985) while the sequence recognised
by 228S/Taq 1 is present on the majority of chromosomes
and is predominantly centromeric in location (D. Turner,
unpublished observations). Bearing in mind that the probes
33.15 and 228S only screen a fraction of the genome and that
none of the low molecular weight DNA below 2 kb in size
can be analysed, the frequency of somatic alterations
observed in ovarian tumours is surprisingly high. These
findings are in keeping with the cytogenetic findings in
ovarian tumours which have revealed a variety of
chromosome deletions, translocations and complete
chromosomal losses all of which are consistent with the
substantial body ofevidence suggesting that an accumulation
ofmultiple genetic events is required for the tumour develop-
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Figure 1 DNA fingerprint patterns of primary ovarian tumour
and metastatic sites from patient BE obtained using minisatellite
probe 33.15/HinfI (a) and 33.15/Alu I (b). Changes in the
minisatellite pattern are marked by arrows. Size markers are
given in kilobase pairs (constitutional DNA is represented by
normal uterine muscle). In a there is reduction in intensity of a
3.8 kb band in all sites, an additional reduction in intensity of a
5.5 kb band in a (peritoneal) metastasis and the appearance of
three new bands in a rectal metastasis. DNA was digested with
Alu I and probed with 33.15 (b) to determine whether the appar-
ent somatic changes were due to DNA methylation which could
cleave HinfI cleavage sites. There was reduction in intensity of a
6 kb band in the peritoneal metastasis and evidence ofnew bands
in the rectal metastasis.
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Figure 2 DNA fingerprint pattern of primary ovarian tumour
and metastatic sites from patient BE obtained following digestion
of DNA with Pst I and probing with 216S. 216S is a minisatellite
probe which recognises bands of consistent restriction fragment
length and gives an invariable banding pattern and was used to
determine if non-random events could be detected in ovarian
tumours. This approach did not appear to be informative and an
example of the identical banding pattern in all tumour sites in
patient BE is demonstrated.
ment and progression. Somatic changes were observed in
70% of ovarian tumours, the most frequent being a deletion,
or decrease in intensity, of a band suggesting loss of
heterozygosity. Loss of heterozygosity has been reported to
occur in a wide range of human tumours and the loss of
regulatory sequences has been implicated to be important in
tumorigenesis and tumour progression (Ponder, 1988;
Hansen & Cavanee, 1988). Additional genomic abnormalities
occurred in ovarian tumours and included increased
intensification of single bands, possibly related to localised
amplification of DNA fragments, and the appearance of new
bands which could have arisen by length changes of pre-
existing minisatellites due to unequal sister chromatid
exchange. Some of the changes could have been due to
tumour specific DNA methylation which would alter the
Hinf I cleavage site and consequently also the hypervariable
DNA fragment length. However, somatic alterations were
also seen following digestion of DNA with Alu 1 and Hae III
suggesting that methylation differences alone could not
account for all the apparent somatic changes. Even so, that
some of the changes were almost certainly methylation
related is significant in view of the evidence that transcription
of genes can be profoundly affected by the degree of methyla-
tion of cytosine residues (Frost & Kerbel, 1981; Razin &
Riggs, 1980). Demethylation could certainly lead to gene
activation and account for many of the changes associated
with tumour progression without necessarily invoking
genomic rearrangements, but its relative significance remains
to be established.
It is not known whether the somatic changes that we have
observed using DNA fingerprint analysis are fundamental to
the pathogenesis and progression of ovarian tumours or are
merely epiphenomena reflecting the accumulating genetic
defects that occur with tumour progression. Furthermore,
due to the polymorphic nature of the probes it is not possible
to determine which, if any, of the changes are non-random.
An attempt was made to screen for the presence of non-
random events using one of a new series of so-called
'invariate' repetitive DNA probes. Unlike the multivariate
minisatellite probes this class of probe recognises bands of
consistent restriction fragment length throughout the popul-
ation (Fowler et al., 1988). Apart from two cases, the band-
ing pattern with invariate probes was identical in all the
tumour and constitutional DNA samples. Although this ap-
proach did not appear to be informative it does not of course
rule out the possibility of common non-random genetic
changes occurring in ovarian tumours.
Cytogenetic analysis has demonstrated the heterogeneous
nature of ovarian tumours, but due to technical limitations it
has not generally been possible to study both the primary
tumour and multiple metastatic sites in the same patient.
DNA fingerprint analysis, however, is well suited to investi-
gation of clonal evolution and heterogeneity within a neo-
plastic cell population. Using this technique ovarian tumours
are demonstrably heterogeneous with different DNA patterns
observed in different sites. Changes in relative band intensity
were accompanied by loss as well as acquisition of fragments
in different sites, and this observation is more consistent with
numerical or structural chromosomal differences in different
sites than with inclusion of different amounts of tumour
tissue in the biopsy specimens. Generally, within an individ-
ual patient, the primary tumour and metastases appear to
share a common DNA fingerprint pattern with minor varia-
tions occurring in different sites, suggesting that the different
populations are derived from a common stem cell. This is in
keeping with the hypothesis that tumour progression results
from acquired genetic variability within the original malig-
nant cell population, with sequential selection of increasingly
genetically altered, and possibly more aggressive, subpopula-
tions (Nowell, 1976). An alternative explanation to account
for the heterogeneous nature of ovarian tumours is that
ovarian tumours may, in some instances, be multifocal in
origin, with tumorigenesis occurring within a field defect in
coelomic epithelium and mesenchyme, (Woodruff & Julian,
1969) resulting in the development of multiple synchronous
primary tumours with a different genetic make-up. Tumours
arising in this fashion would be expected to show a high
degree of site-to-site variability on DNA fingerprint analysis
and this is therefore not fully supported by the relatively
minor variations demonstrated in the majority of patients in
the study. However, the number of patients in this study is
,oo few to refute the possibility of multifocal tumorigenesis
occurring in a proportion of patients with widespread
gynaecological neoplasia. The identification of patients with
'extensive disease' as a result of carcinogenesis occurring in a
field defect should be pursued and DNA fingerprint analysis
could prove to be useful in this regard.
This study clearly demonstrates that DNA fingerprint
analysis is a sensitive method to detect somatic changes in
tumour DNA and for investigating the development of clonal
heterogeneity in ovarian tumours. The most frequent abnor-
mality observed was a deletion or decrease in intensity of a
band suggesting loss of heterozygosity and as a natural
extension of the study we are now attempting to isolate and
clone the fragments present in constitutional DNA that have
been deleted in corresponding tumour DNA in selected
patients. This strategy has previously been successful and a
large hypervariable DNA fragment from a human DNA
fingerprint has recently been isolated, purified and cloned
(Wong et al., 1986). The fragment contained multiple copies
of a 37 bp repeat unit but was flanked by non-repetitive
unique sequence DNA that hybridised to a single locus on
chromosome 7 and which has subsequently been used to
detect chromosome 7 loss in myelodysplasia (Thein et al.,
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1988). It should therefore be possible to obtain locus-specific
hybridisation probes by isolating and cloning selected
fragments in DNA fingerprints obtained from patients with
ovarian tumours and to use these probes to determine the
frequency and biological significance of genomic re-
arrangements at these various loci in a larger cohort of
patients with ovarian cancer.
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